Logo image of EDSA

EDESA BIOTECH INC (EDSA) Stock Price, Quote, News and Overview

NASDAQ:EDSA - Nasdaq - CA27966L3065 - Common Stock - Currency: USD

1.99  -0.02 (-1%)

After market: 1.95 -0.04 (-2.01%)

EDSA Quote, Performance and Key Statistics

EDESA BIOTECH INC

NASDAQ:EDSA (5/28/2025, 8:00:02 PM)

After market: 1.95 -0.04 (-2.01%)

1.99

-0.02 (-1%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.59
52 Week Low1.55
Market Cap13.97M
Shares7.02M
Float5.65M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07
IPO08-25 2008-08-25


EDSA short term performance overview.The bars show the price performance of EDSA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

EDSA long term performance overview.The bars show the price performance of EDSA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of EDSA is 1.99 USD. In the past month the price decreased by -16.03%. In the past year, price decreased by -54.04%.

EDESA BIOTECH INC / EDSA Daily stock chart

EDSA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.83 323.41B
AMGN AMGEN INC 13.41 149.70B
GILD GILEAD SCIENCES INC 14.01 134.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.30B
REGN REGENERON PHARMACEUTICALS 13.36 63.90B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.23B
ARGX ARGENX SE - ADR 98.17 35.18B
ONC BEIGENE LTD-ADR 6.16 25.99B
BNTX BIONTECH SE-ADR N/A 23.45B
NTRA NATERA INC N/A 22.01B
SMMT SUMMIT THERAPEUTICS INC N/A 19.34B
BIIB BIOGEN INC 8.06 18.69B

About EDSA

Company Profile

EDSA logo image Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. The company is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. The company has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The company is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.

Company Info

EDESA BIOTECH INC

100 Spy Crt

Markham ONTARIO L3R 5H6 CA

CEO: Pardeep Nijhawan

Employees: 16

EDSA Company Website

EDSA Investor Relations

Phone: 19054751234

EDESA BIOTECH INC / EDSA FAQ

What is the stock price of EDESA BIOTECH INC today?

The current stock price of EDSA is 1.99 USD. The price decreased by -1% in the last trading session.


What is the ticker symbol for EDESA BIOTECH INC stock?

The exchange symbol of EDESA BIOTECH INC is EDSA and it is listed on the Nasdaq exchange.


On which exchange is EDSA stock listed?

EDSA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EDESA BIOTECH INC stock?

7 analysts have analysed EDSA and the average price target is 19.38 USD. This implies a price increase of 873.87% is expected in the next year compared to the current price of 1.99. Check the EDESA BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EDESA BIOTECH INC worth?

EDESA BIOTECH INC (EDSA) has a market capitalization of 13.97M USD. This makes EDSA a Nano Cap stock.


How many employees does EDESA BIOTECH INC have?

EDESA BIOTECH INC (EDSA) currently has 16 employees.


What are the support and resistance levels for EDESA BIOTECH INC (EDSA) stock?

EDESA BIOTECH INC (EDSA) has a support level at 1.95 and a resistance level at 2. Check the full technical report for a detailed analysis of EDSA support and resistance levels.


Should I buy EDESA BIOTECH INC (EDSA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EDESA BIOTECH INC (EDSA) stock pay dividends?

EDSA does not pay a dividend.


When does EDESA BIOTECH INC (EDSA) report earnings?

EDESA BIOTECH INC (EDSA) will report earnings on 2025-08-07.


What is the Price/Earnings (PE) ratio of EDESA BIOTECH INC (EDSA)?

EDESA BIOTECH INC (EDSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.59).


What is the Short Interest ratio of EDESA BIOTECH INC (EDSA) stock?

The outstanding short interest for EDESA BIOTECH INC (EDSA) is 0.73% of its float. Check the ownership tab for more information on the EDSA short interest.


EDSA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

EDSA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EDSA. While EDSA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EDSA Financial Highlights

Over the last trailing twelve months EDSA reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS increased by 34.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -146.71%
ROE -269.83%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%48.28%
Sales Q2Q%N/A
EPS 1Y (TTM)34.3%
Revenue 1Y (TTM)N/A

EDSA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to EDSA. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners6.38%
Ins Owners7.98%
Short Float %0.73%
Short Ratio1.86
Analysts
Analysts82.86
Price Target19.38 (873.87%)
EPS Next Y29.97%
Revenue Next YearN/A